Please login to the form below

Not currently logged in
Email:
Password:

schizophrenia

This page shows the latest schizophrenia news and features for those working in and with pharma, biotech and healthcare.

Alkermes slumps as FDA turns down depression drug

Alkermes slumps as FDA turns down depression drug

The setback for ALKS 5461 will leave Alkermes more reliant on a positive read-out for schizophrenia candidate ALKS 3831, with two phase III trials due to report later this year.

Latest news

  • Biogen pays $590m for Pfizer cognition drug Biogen pays $590m for Pfizer cognition drug

    Biogen pays $590m for Pfizer cognition drug. Early stage studies look positive for schizophrenia drug. ... Biogen has added another drug to its neuroscience pipeline, paying $75m upfront for rights to a Pfizer drug in development for cognitive impairment

  • Takeda explores the potential of ‘digital biomarkers’ Takeda explores the potential of ‘digital biomarkers’

    Takeda is exploring the potential of ‘digital biomarkers’to help develop new mental health treatments, with a particular focus on schizophrenia and treatment-resistant depression.

  • Novartis plans digital therapeutics for schizophrenia and MS Novartis plans digital therapeutics for schizophrenia and MS

    Novartis plans digital therapeutics for schizophrenia and MS. Will work with Pear Therapeutics on a prescription software range. ... They will look to do this by advancing the clinical development of Pear’s Thrive digital therapeutic for patients with

  • Boehringer abandons PDE-targeted Alzheimer’s drug Boehringer abandons PDE-targeted Alzheimer’s drug

    Boehringer abandons PDE-targeted Alzheimer’ s drug. But will keep testing the candidate in schizophrenia. ... The company says it will now shift the focus of BI 409306 to schizophrenia, another disease which seems to involve disruption of the glutamate

  • Boehringer adds to pipeline again with €628m Autifony CNS deal Boehringer adds to pipeline again with €628m Autifony CNS deal

    Boehringer adds to pipeline again with 628m Autifony CNS deal. Bags rights to the GlaxoSmithKline spin-out's small-molecule drug for schizophrenia. ... of mental disorders, such as schizophrenia, Alzheimer’s disease and depression, ”he added.

More from news
Approximately 26 fully matching, plus 253 partially matching documents found.

Latest Intelligence

  • A new era of smart pharma A new era of smart pharma

    According to a systematic review of 39 studies, published in Clinical Psychology in 2002, a mean rate of medication non-adherence in schizophrenia sufferers is 41%, one of the highest of ... Furthermore, given the serious negative effects of

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    Rates of adherence are especially low among patients with chronic conditions such as COPD (33%), schizophrenia (52%) and asthma (67%). ... 80% in just five disease areas - asthma, type 2 diabetes, coronary heart disease, hypertension and schizophrenia -

  • Digital disruption Digital disruption

    Starting with projects in schizophrenia and Parkinson’s disease, Lundbeck and IBM will also work together to identify potential new drug targets and alternative indications.

  • Pharma deals in February 2015 Pharma deals in February 2015

    in-house clinical and preclinical pipeline targeting serious diseases with blockbuster potential eg Alzheimer's disease, ADHD, metabolic disease, schizophrenia, migraine.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc.

More from intelligence
Approximately 2 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics